Developing Transformative Therapies for Patients with Fibrotic Disease
Arxx Therapeutics develops a first-in-class monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis
We are committed to improve and extend the lives of people suffering from fibrotic disease. We use science-driven innovation to develop therapies with the potential to transform the management of fibrosis and help the many patients poorly served by current therapeutic options.
We are leveraging more than 30 years of research by our scientific co-founders uncovering the pathobiology of S100A4; a Damage Associated Molecular Pattern protein upregulated upon stress or injury allowing cells to sense and react to danger. In chronically diseased tissue, S100A4 is inappropriately activated which leads to persistent inflammation and non-resolving tissue fibrosis. Our lead candidate AX-202 is a high-affinity monoclonal antibody neutralizing the bioactivity of S100A4. AX-202 confers targeted, upstream and disease-specific modulation of the self-sustaining feedback loop driving persistent fibrogenesis.